<VariationArchive VariationID="2678827" VariationName="NM_014251.3(SLC25A13):c.89dup (p.Asn30fs)" VariationType="Duplication" Accession="VCV002678827" Version="2" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-02-29" DateCreated="2023-12-30" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2838545" VariationID="2678827">
      <GeneList>
        <Gene Symbol="SLC25A13" FullName="solute carrier family 25 member 13" GeneID="10165" HGNC_ID="HGNC:10983" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>7q21.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="96120220" stop="96322098" display_start="96120220" display_stop="96322098" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="95749531" stop="95951458" display_start="95749531" display_stop="95951458" Strand="-" />
          </Location>
          <OMIM>603859</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_014251.3(SLC25A13):c.89dup (p.Asn30fs)</Name>
      <CanonicalSPDI>NC_000007.14:96277318:TTTTT:TTTTTT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>7q21.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="96277318" stop="96277319" display_start="96277318" display_stop="96277319" variantLength="1" positionVCF="96277318" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="95906630" stop="95906631" display_start="95906630" display_stop="95906631" variantLength="1" positionVCF="95906630" referenceAlleleVCF="G" alternateAlleleVCF="GT" />
      </Location>
      <ProteinChange>N30fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.13" sequenceAccession="NC_000007" sequenceVersion="13" change="g.95906635dup" Assembly="GRCh37">
            <Expression>NC_000007.13:g.95906635dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_014251.3" sequenceAccession="NM_014251" sequenceVersion="3" change="c.89dup" MANESelect="true">
            <Expression>NM_014251.3:c.89dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_055066.1" sequenceAccession="NP_055066" sequenceVersion="1" change="p.Asn30fs">
            <Expression>NP_055066.1:p.Asn30fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_027662.2" sequenceAccession="NR_027662" sequenceVersion="2" change="n.231dup">
            <Expression>NR_027662.2:n.231dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.14" sequenceAccession="NC_000007" sequenceVersion="14" change="g.96277323dup" Assembly="GRCh38">
            <Expression>NC_000007.14:g.96277323dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012247.2" sequenceAccession="NG_012247" sequenceVersion="2" change="g.49829dup">
            <Expression>NG_012247.2:g.49829dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001160210.2" sequenceAccession="NM_001160210" sequenceVersion="2" change="c.89dup">
            <Expression>NM_001160210.2:c.89dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001153682.1" sequenceAccession="NP_001153682" sequenceVersion="1" change="p.Asn30fs">
            <Expression>NP_001153682.1:p.Asn30fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.89dup (p.Asn30fs) AND Citrullinemia, type II, adult-onset" Accession="RCV003472803" Version="1">
        <ClassifiedConditionList TraitSetID="65850">
          <ClassifiedCondition DB="MedGen" ID="CN295299">Citrullinemia, type II, adult-onset</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-05-10" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_014251.3(SLC25A13):c.89dup (p.Asn30fs) AND Citrin deficiency" Accession="RCV003741356" Version="1">
        <ClassifiedConditionList TraitSetID="9638">
          <ClassifiedCondition DB="MedGen" ID="C1997910">Citrin deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-01-29" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-05-10" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2023-12-30" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10369257</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">14680984</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27405544</ID>
        </Citation>
        <DescriptionHistory Dated="2024-02-17">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="9638" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6541" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Citrin deficiency</ElementValue>
                <XRef ID="MONDO:0016602" DB="MONDO" />
                <XRef ID="429735007" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="20661" />
                <XRef ID="20661" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, ACT Sheet, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, [Elevated Citrulline], Amino Acidemia/Urea Cycle Disorder, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Elevated Citrulline: Amino Acidemia Algorithm, 2022</CitationText>
              </Citation>
              <XRef ID="247582" DB="Orphanet" />
              <XRef ID="C1997910" DB="MedGen" />
              <XRef ID="MONDO:0016602" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="65850" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="55843" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Citrullinemia, type II, adult-onset</ElementValue>
                <XRef ID="MONDO:0011326" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Adult-onset citrullinemia type 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CTLN2</ElementValue>
                <XRef Type="MIM" ID="603471" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Citrin deficiency can manifest in newborns or infants as neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), in older children as failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD), and in adults as recurrent hyperammonemia with neuropsychiatric symptoms in citrullinemia type II (CTLN2). Often citrin deficiency is characterized by strong preference for protein-rich and/or lipid-rich foods and aversion to carbohydrate-rich foods. NICCD. Children younger than age one year have a history of low birth weight with growth restriction and transient intrahepatic cholestasis, hepatomegaly, diffuse fatty liver, and parenchymal cellular infiltration associated with hepatic fibrosis, variable liver dysfunction, hypoproteinemia, decreased coagulation factors, hemolytic anemia, and/or hypoglycemia. NICCD is generally not severe and symptoms often resolve by age one year with appropriate treatment, although liver transplantation has been required in rare instances. FTTDCD. Beyond age one year, many children with citrin deficiency develop a protein-rich and/or lipid-rich food preference and aversion to carbohydrate-rich foods. Clinical abnormalities may include growth restriction, hypoglycemia, pancreatitis, severe fatigue, anorexia, and impaired quality of life. Laboratory changes are dyslipidemia, increased lactate-to-pyruvate ratio, higher levels of urinary oxidative stress markers, and considerable deviation in tricarboxylic acid (TCA) cycle metabolites. One or more decades later, some individuals with NICCD or FTTDCD develop CTLN2. CTLN2. Presentation is sudden and usually between ages 20 and 50 years. Manifestations are recurrent hyperammonemia with neuropsychiatric symptoms including nocturnal delirium, aggression, irritability, hyperactivity, delusions, disorientation, restlessness, drowsiness, loss of memory, flapping tremor, convulsive seizures, and coma. Symptoms are often provoked by alcohol and sugar intake, medication, and/or surgery. Affected individuals may or may not have a prior history of NICCD or FTTDCD.</Attribute>
                <XRef ID="NBK1181" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301360</ID>
                <ID Source="BookShelf">NBK1181</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Citrullinemia_II_Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Citrin Deficiency, Citrullinemia II, Urea Cycle Disorder, 2012</CitationText>
              </Citation>
              <XRef ID="247585" DB="Orphanet" />
              <XRef ID="CN295299" DB="MedGen" />
              <XRef ID="MONDO:0011326" DB="MONDO" />
              <XRef Type="MIM" ID="603471" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7856849" SubmissionDate="2023-12-07" DateLastUpdated="2023-12-30" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_014251.3:c.89dup|OMIM:603471" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004201636" DateUpdated="2023-12-30" DateCreated="2023-12-30" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_014251.3:c.89dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603471" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8220204" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="18283586|MedGen:C1997910" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004435959" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-29">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10369257</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">14680984</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27405544</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with SLC25A13-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.007%). This sequence change creates a premature translational stop signal (p.Asn30Lysfs*3) in the SLC25A13 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC25A13 are known to be pathogenic (PMID: 10369257, 14680984, 27405544).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SLC25A13" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000007.13:g.95906630_95906631insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1997910" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7856849" TraitType="Disease" MappingType="XRef" MappingValue="603471" MappingRef="OMIM">
        <MedGen CUI="CN295299" Name="Citrullinemia, type II, adult-onset" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8220204" TraitType="Disease" MappingType="XRef" MappingValue="C1997910" MappingRef="MedGen">
        <MedGen CUI="C1997910" Name="Citrin deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

